High-Frequency Repetitive Transcranial Magnetic Stimulation Over the Left Dorsolateral Prefrontal Cortex Shortly Alleviates Fatigue in Patients With Multiple System Atrophy: A Randomized Controlled Trial

Jing Pan 1,2, Tao-Mian Mi 1,3, Jing-Hong Ma 1,3, Hong Sun 1,3 and Piu Chan 1,3,4*

1 Department of Neurology, Neurobiology and Geriatrics, Xuanwu Hospital of Capital Medical University, Beijing Institute of Neurology, Beijing, China, 2 Department of Neurology, The Second Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China, 3 Clinical Center for Parkinson’s Disease, Key Laboratory for Neurodegenerative Disease of the Ministry of Education, Beijing Key Laboratory for Parkinson’s Disease, Parkinson’s Disease Center of Beijing Institute of Brain Disorders, Collaborative Innovation Center for Brain Disorders, Xuanwu Hospital of Capital Medical University, Beijing, China, 4 National Clinical Research Center for Geriatric Disorders, Xuanwu Hospital of Capital Medical University, Beijing, China

Background: Fatigue is a common symptom in patients with Multiple system atrophy (MSA), but effective treatments remain elusive. The present study aims to investigate whether high-frequency repetitive transcranial magnetic stimulation (rTMS) over the left dorsolateral prefrontal cortex (DLPFC) could relieve fatigue in patients with MSA.

Methods: This is a single-center, randomized and double-blind trial. Twenty-two patients with MSA and fatigue were randomly allocated to receive 10 sessions of either active (N = 11) or sham (N = 11) 10 Hz rTMS over the left DLPFC. The participants were assessed at baseline (T0), after the last session of treatment (T1), and at 2-week (T2), and 4-week (T3) follow-up timepoints. The primary outcomes were Fatigue Severity Scale-9 (FSS-9) scores, with Unified Multiple System Atrophy Rating Scale (UMSARS), 17-item Hamilton Depression Scale (HAMD-17), and Hamilton Anxiety Scale (HAMA) as secondary outcomes.

Results: Two-way repeated ANOVAs revealed significant group × time interactions for FSS-9 scores (p < 0.001), HAMD-17 scores (p = 0.01), HAMA scores (p = 0.01), and UMRSA part II (p = 0.05). Post-hoc analyses showed that compared to T0, the active group exhibited remarkable improvements in FSS-9 and UMRSA part II scores at T1 and T2, but not at T3, and also in HAMD-17 and HAMA scores at T1, T2, and T3. No significant improvement was found in the sham group.
INTRODUCTION

Multiple system atrophy (MSA), an orphan, adult-onset, sporadic, progressive neurodegenerative disease, is characterized by Parkinsonian features, cerebellar ataxia, and autonomic failure in various combinations (1). Early and severe autonomic failure is a core feature of MSA, including fatigue (2). Studies have shown that fatigue, an independent non-motor symptom, is one of the most common and major problems for 38–61% MSA patients, which contributes greatly to reduced social participation and quality of life (3–5). Treatment of fatigue can be very challenging, as till now there is no widely accepted treatment regimen throughout the trial. Exclusion criteria include: (a) Mini-Mental State Examination scores (MMSE) ≥36, and (c) stable anti-Parkinsonian therapy for ≥4 weeks and constant medication regimens throughout the trial. Inclusion criteria were: (a) 30–75 years old, (b) Presence of clinical fatigue: Fatigue Severity Scale-9 (FSS) ≥36, and (c) stable anti-Parkinsonian therapy for ≥4 weeks and constant medication regimens throughout the trial. Exclusion criteria included: (a) Mini-Mental State Examination scores (MMSE) ≤24, (b) presence of contraindications for rTMS. The study protocol was approved and supervised by the Xuanwu Hospital Ethics Committee; all patients had agreed and confirmed informed consent prior to the study. The present study was registered at the Clinical Trial Registration (http://www.clinicaltrials.gov, NCT 04313530).

Experimental Design

This study was a single-center, randomized, double-blind, and sham-controlled trial, in which the 22 participants were randomly assigned (with 1:1 ratio) with sealed envelopes into two groups to receive either 10-Hz rTMS (N = 11) or sham stimulation (N = 11) over the left DLPFC. Both the participants and researchers were blind to the randomization group, only the clinician responsible for the rTMS protocols was unmasked to the randomization sequence.

rTMS and Sham Protocols

Magnetic stimulation was applied using a 7-cm, handheld, figure-of-eight coil was connected to a biphasic magnetic stimulator (Magstim Rapid; TheMagstim Co. Ltd., UK). The treatment protocol was performed in a total of 10 sessions over two successive weeks, consisting of one session per day for five consecutive days followed by a 1-day interval. Intervention was given at approximately the same time of day for each participant. The rTMS parameters used in the present study were referred to several previous studies, which have reported beneficial effects of rTMS on fatigue (11–14). That is, each session consisted of 20 series of 2-s 10 Hz pulses followed by a 18 s interval, with an intensity of 100% resting motor threshold (RMT), which gave a total of 1,200 pulses per session. The RMT is defined as the minimum intensity to evoke a visible voluntary contraction of the target muscle, the thenar muscles of the right hand, in 50% of successive trials. The coil was oriented at a 45° angle to the midsagittal plane (15) and was fixed to an arm that could be adjusted in three dimensions. Sham stimulation protocol was same as the rTMS protocol, except the coil was oriented at a 90° angle to the midsagittal plane (15), which could produce similar sounds and sensations as active stimulation while not inducing currents within the brain. All the participants were arranged at different time to avoid them from discussing with each other which ensured blinding during the data collection process.

Clinical Assessments

The participants underwent clinical assessments at baseline (T0), and three follow-up timepoints, that is, immediately after the tenth treatment session (T1), 2 weeks (T2), and 4 weeks (T3) after T1. The primary outcome was the FSS score, a self-reported scale for assessing the fatigue severity over the last 2 weeks. The secondary outcomes were the part I and II of the Unified

Conclusion: High-frequency rTMS over the left DLPCF could provide short-term improvements for alleviating fatigue in patients with MSA, but the beneficial effects last no more than 4 weeks.

Keywords: transcranial magnetic stimulation, the left dorsolateral prefrontal cortex, multiple system atrophy, fatigue, effective
Multiple System Atrophy Rating Scale (UMSARS), the Hamilton Depression Scale (HAM-D), and the Hamilton Anxiety Scale (HAMA), which were used to assess motor performance and non-motor symptoms, respectively.

Side Effects
The safety of rTMS was assessed by monitoring the occurrence of adverse effects for all patients during the whole study process. These side effects were recorded at the T0, T1, T2, and T3 timepoints and were grouped into the following categories: (1) headache, (2) site discomfort, (3) nausea, (4) dizziness, and (5) others.

Statistical Analysis
All statistical analyses were performed using SPSS Version 26 (IBM, Chicago, IL, USA). Demographic data were presented as mean ± SD for continuous variables and ratios or percentages for categorical variable. Independent two samples t-test was used to compare continuous variables, and the χ²-test was performed for the comparison of categorical variables. Two-way repeated ANOVA, with Group (rTMS/sham group) as between-subject factor and Time (T0, T1, T2, T3) as within-subject factor, was applied to estimate the effects of rTMS on the clinical outcomes. The threshold for the level of significance was set at α = 0.05. In all cases, P-values < 0.05 was considered to defined as statistically significant result.

RESULTS
Participants
The demographic and clinical characteristics of the participants are presented in Table 1. The rTMS and sham group had similar baseline characteristics including age, gender, H-Y stage, levodopa-equivalent daily dose (LEDD), UMSARS scores, HAMA, HAMD, GDS, MMSE, and MoCA. The severity of fatigue was basically the same between the two groups.

Clinical Efficacy: Primary Outcome
As shown in Table 2 and Figure 1, in the comparison of FSS score, there was a significant Group × Time interaction (p < 0.01), as well as significant Group (p = 0.02), and Time (p < 0.001) main effects. Post-hoc analyses showed that compared to T0, the rTMS group exhibited remarkable improvements in FSS-9 scores at T1 and T2, but not at T3. No significant improvement was found in the sham group.

Clinical Efficacy: Secondary Outcomes
Our analyses revealed significant Group × Time interactions for HAMA scores (P = 0.01), HAMD scores (P = 0.01), and UMSARS-II scores (P = 0.05), indicating that rTMS yielded improvements in these scores compared to sham stimulation. Post-hoc analyses showed that compared to T0, HAMA, and HAMD scores were significantly reduced in rTMS group at T1, T2, and T3; while the UMSARS-II scores were significantly improved at T1 and T2, but not at T3. We did not find any significant Group × Time interaction in the comparison of UMSARS-I scores.

TABLE 1 | Demographic and clinical features of participants.

| Variables                        | rTMS group (N = 11) | Sham group (N = 11) | P     |
|----------------------------------|--------------------|--------------------|-------|
| Gender (female/male)             | 6/5                | 6/5                | 1.00  |
| Age (years)                      | 58.64 ± 5.50       | 59.00 ± 6.02       | 0.73  |
| Disease duration (years)         | 2.00 ± 1.00        | 1.91 ± 1.22        | 0.35  |
| Subtypes (MSA-P/MSA-C)           | 6/5                | 4/7                | 1.00  |
| H-Y stage                        | 2.95 ± 1.19        | 2.86 ± 1.23        | 0.44  |
| UMSARS-I                         | 18.45 ± 8.03       | 22.45 ± 6.76       | 0.99  |
| UMSARS-II                        | 18.82 ± 9.31       | 20.27 ± 8.01       | 0.91  |
| UMSARS IV                        | 2.18 ± 1.25        | 2.72 ± 1.27        | 0.48  |
| LEDD (mg/d)                      | 295.45 ± 313.41    | 234.09 ± 296.80    | 0.37  |
| MMSE                             | 28.64 ± 1.86       | 27.64 ± 1.57       | 0.49  |
| MoCA                             | 23.82 ± 3.40       | 22.91 ± 3.75       | 0.69  |
| FSS                              | 51.36 ± 10.58      | 51.73 ± 8.92       | 0.28  |
| HAMA                             | 16.82 ± 10.83      | 14.27 ± 5.95       | 0.09  |
| HAMD                             | 15.27 ± 7.17       | 12.45 ± 5.24       | 0.25  |
| GDS                              | 17.09 ± 7.09       | 16.45 ± 6.31       | 0.53  |
| ESS                              | 7.72 ± 6.96        | 5.18 ± 3.49        | 0.23  |
| RBDQ-HK                          | 25.27 ± 13.30      | 23.18 ± 15.62      | 0.57  |
| ADL                              | 27.27 ± 11.74      | 33.18 ± 11.96      | 0.71  |

Continuous variables are represented by Means and standard deviations. ADL, activities of daily living; ESS, Epworth Sleepiness Scale; FSS, Fatigue Severity Scale; HAMA, Hamilton Anxiety Scale; HAMD, Hamilton Depression Scale; H–Y stage, Hoehn and Yahr stage; LEDD, levodopa-equivalent daily dose; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; MSA-C, Cerebellar subtype of Multiple system atrophy; MSA-P, Parkinsonism subtype of Multiple system atrophy; UMSARS I, Unified Multiple-System Atrophy Rating Scale Part I: historical; UMSARS II, Unified Multiple-System Atrophy Rating Scale Part II: motor examination; UMSARS IV, Unified Multiple-System Atrophy Rating Scale Part IV: global disability scale; RBDQ-HK, Rapid-eye-movement Sleep Behavior Disorder Questionnaire HongKong.

Adverse Events
Few transient and minor adverse events were reported during the stimulation sessions only. Two patients in the rTMS group reported mild and transient headaches after the first session, which lasted around 10 min; while one patient in the sham group reported minor dizziness after the first stimulation.

DISCUSSION
In this randomized, double-blind, sham-controlled study, we demonstrated that high-frequency rTMS over the left DLPFC induced a short-lasting improvement in fatigue in patients with MSA. In addition, patients’ motor symptoms, as well as depression and anxiety symptoms, were also shortly improved to a certain extent after the active rTMS. Though the beneficial effects lasted no more than 4 weeks, we suggest that the high-frequency rTMS over the left DLPFC could still be used as an available therapeutic protocol for alleviating fatigue in patients with MSA.

The beneficial effects of rTMS on fatigue have been previously reported in several neurological disorders, such as fibromyalgia, myalgic encephalomyelitis, and multiple sclerosis, as fatigue
is a common symptom in these disorders and contributes substantially to decrements in quality of life and disability (15). A randomized-controlled trial provided evidence that 4 weeks of daily high-frequency (10 Hz) rTMS over the left DLPFC rTMS is able to improve fatigue in patients with fibromyalgia, and provided impetus that the utility rTMS may be an available approach for the relief of fatigue in related disorders (11). Another similar study investigating rTMS effect in patients with fibromyalgia revealed significant improvements in fatigue, depression, and quality of life in the rTMS treatment group when accepting daily high-frequency (10 Hz) rTMS to the left DLPFC over 3 weeks (12). Recently, Yang et al. (13) reported that rTMS over the left DLPFC improves fatigue in patients with myalgic encephalomyelitis and suggested that rTMS can be a novel therapeutic intervention for fatigue. None of the patients previously experienced serious side effects in these studies, which provide compelling evidence for the safety of rTMS treatment. These studies suggest that 10 Hz rTMS over the left DLPFC may be an effective and safe strategy to relieve fatigue in patients with chronic neurological disorders. In the present study, similarly, our findings also provided evidence for the beneficial effects of rTMS, indicating that high-frequency rTMS over the left DLPFC may be a safe and effective therapy for alleviating fatigue in patients with MSA.

It is well-known that the most common and widely used site for rTMS relieving depression is DLPFC (15–18). High-frequency rTMS over the left DLPFC has been suggested as Level A evidence (definite efficacy) for relieving depression, and as Level B evidence (probable efficacy) for improving Parkinson’s disease related depression (19). Though fatigue and depression have some clinical features in common, fatigue is distinguishable from depression and indeed an independent entity from depression (20). Fatigue refers to subjective sensations of weariness, increasing sense of effort, mismatch between effort expended and actual performance, or exhaustion (20). However, fatigue and depression, both of which are common non-motor symptoms in patients with MSA, do have similar pathophysiological mechanisms, including serotonergic dysfunction in basal ganglia and limbic circuits, which contribute to dysfunction of prefrontal-basal ganglia loops and impaired integration of limbic input and motor functions (6). Although no evidence-based guidelines have been proposed on the therapeutic use of rTMS for fatigue yet (19), the left DLPFC has been chosen as the optimal stimulation target for fatigue treatment in several previous studies (11–13). Here, we used the same stimulation target and demonstrated similar favorable results. It has been generally suggested that rTMS can not only generate biological effects on the stimulation site per se, but also on other distant sites connected by the activated networks (21). High-frequency rTMS generates a remarkable change of blood-oxygen-level-dependent (BOLD) signal within large and distant areas of the cortex (22). Several studies have also

### Table 2: Clinical efficiency of the rTMS and Sham group.

|               | rTMS group | Sham group | DF  | F    | P    |
|---------------|------------|------------|-----|------|------|
| **FSS**       |            |            |     |      |      |
| T0            | 51.36 ± 10.58 | 51.73 ± 8.92 | Group | 1 | 6.13 | 0.02 |
| T1            | 32.00 ± 9.45 | 49.91 ± 9.85 | Time | 1 | 36.34 | <0.001 |
| T2            | 36.91 ± 7.27 | 50.82 ± 7.65 | Group × time | 1 | 21.53 | <0.001 |
| T3            | 51.91 ± 9.05 | 53.36 ± 7.46 |     |     |      |
| **HAMA**      |            |            |     |      |      |
| T0            | 16.82 ± 10.83 | 14.27 ± 5.95 | Group | 1 | 0.56 | 0.46 |
| T1            | 9.36 ± 6.71 | 13.64 ± 4.93 | Time | 1.60 | 7.09 | 0.01 |
| T2            | 11.48 ± 7.17 | 14.55 ± 5.17 | Group × time | 1.60 | 6.28 | 0.01 |
| T3            | 11.64 ± 8.71 | 15.27 ± 5.24 |     |     |      |
| **HAMD**      |            |            |     |      |      |
| T0            | 15.27 ± 7.17 | 12.45 ± 5.24 | Group | 1 | 2.34 | 0.14 |
| T1            | 7.64 ± 2.69 | 12.64 ± 4.27 | Time | 1.92 | 4.29 | 0.02 |
| T2            | 10.27 ± 4.54 | 13.09 ± 3.89 | Group × time | 1.92 | 5.83 | 0.01 |
| T3            | 9.91 ± 4.28 | 14.36 ± 4.39 |     |     |      |
| **UMSARS-I**  |            |            |     |      |      |
| T0            | 18.45 ± 8.03 | 22.45 ± 6.76 | Group | 1 | 2.22 | 0.15 |
| T1            | 17.55 ± 7.83 | 22.18 ± 8.32 | Time | 1.49 | 4.58 | 0.03 |
| T2            | 18.00 ± 7.71 | 23.27 ± 7.55 | Group × time | 1.49 | 1.13 | 0.32 |
| T3            | 18.73 ± 7.70 | 24.09 ± 7.52 |     |     |      |
| **UMSARS-II** |            |            |     |      |      |
| T0            | 18.82 ± 9.32 | 20.27 ± 8.01 | Group | 1 | 0.59 | 0.45 |
| T1            | 17.18 ± 8.55 | 20.73 ± 8.10 | Time | 1.84 | 10.48 | <0.001 |
| T2            | 18.36 ± 9.20 | 21.64 ± 8.10 | Group × time | 1.84 | 3.43 | 0.05 |
| T3            | 19.45 ± 9.08 | 22.36 ± 8.43 |     |     |      |

Continuous variables are represented by Means and standard deviations. FSS, Fatigue Severity Scale; HAMA, Hamilton Anxiety Scale; HAMD, Hamilton Depression Scale; UMSARS I, Unified Multiple-System Atrophy Rating Scale Part I: historical; UMSARS II, Unified Multiple-System Atrophy Rating Scale Part II: motor examination.
proven that high-frequency rTMS of the DLPFC can increase dopamine release within basal ganglia (23, 24). Furthermore, the effects of high-frequency rTMS might be the result of not only a direct enhancement of motor cortex excitability (25), but also a decrease of inhibitory γ-aminobutyric acid (GABA) neurotransmission-mediated intracortical inhibition (26). Therefore, high-frequency rTMS over DLPFC is assumed to increase the cortex excitability and dopamine release and modulate cortical plastic, which may impart a beneficial effect on fatigue symptom.

In the present study, though we found that rTMS could improve fatigue in MSA patients, the beneficial effect lasted no more than 4 weeks. Differently, in another two randomized, placebo-controlled trials (11, 12), both studies showed long-term favorable rTMS effects on relieving fatigue in patients with fibromyalgia. Such discrepancy may be attributed to the different parameters used in our study, that is, with an intensity of 100% RMT (vs. 120% RMT in their studies), 1,200 pluses per session (vs. 3,000 pulses) and a total of 2 weeks duration (vs. 4 weeks). More importantly, MSA is characterized by a relentless worsening of motor and non-motor symptoms, with a more rapid progression at the onset (1); whereas fibromyalgia is a mild chronic disorder (11). This indicates that at the time of follow-up, patients may already experience aggravation of motor symptoms and non-motor symptoms, which may also contribute to the inconsistency.

In addition, our results showed that rTMS over left DLPFC could also improve depression and anxiety, as well as motor symptoms in patients with MSA. It is generally known that rTMS over the left DLPFC could improve depression, including Parkinson’s disease-related depression (16–18). The improvements in MSA-related depression symptoms observed in our study are consistent with the results of many previous studies. Motor symptom scores were also statistically significant improvement between the two groups. As noted previously, the magnetic stimulus has distant actions, which means it not only activates local inter-neuronal circuits, but also those fibers projecting to distant structures. The distant actions of rTMS were initially demonstrated in some studies, which showed that rTMS over the DLPFC can modulated M1 excitability, even at a higher extent than direct M1 stimulation itself.

FIGURE 1 | Clinical score changes after the rTMS, including FSS, HAMA, HAMD, UMSARS-I and UMSARS-II scores. Red, rTMS group; black, sham group. *Post-hoc analysis shows significant difference as compared to the baseline (T0) in the group.
(15, 17). It may provide evidence that motor symptoms were improved through rTMS stimulating over the DLPFC in our study.

Our study has several limitations. First, the study was conducted in a single center and the number of participants is relatively small. Second, as the diagnosis of early MSA is full of challenge, only patients with a clear diagnosis were enrolled in our study, indicating a relatively more severe disease. Future studies with a bigger sample size enrolling more MSA patients in the early stage are warranted to clarify the rTMS effect on fatigue in MSA patients.

CONCLUSIONS

In conclusion, our findings suggest that high-frequency rTMS over left DLPFC may ultimately serve as an add-on therapy for alleviating fatigue in MSA patients, though the beneficial effects last no more than 4 weeks. In the future, more optimistic rTMS protocols and techniques are needed to prolong the treatment effect in routine clinical practice.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

REFERENCES

1. Fanciulli A, Wenning GK. Multiple-system atrophy. N Engl J Med. (2015) 372:249–63. doi: 10.1056/NEJMra1311488
2. Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. (2008) 71:670–6. doi: 10.1212/01.wnl.0000324265.0404.15
3. Zhang JY, Cao B, Ou RW, Wei QQ, Zhao B, Yang J, et al. Non-motor symptoms and the quality of life in multiple system atrophy with different subtypes. Parkinsonism Relat Disord. (2017) 35:63–8. doi: 10.1016/j.parkreldis.2016.12.007
4. McKay JH, Cheshire WP. First symptoms in multiple system atrophy. Clin Auton Res. (2018) 28:215–21. doi: 10.1007/s10286-017-0500-0
5. Kluger BM, Herlofson K, Terao Y, Tsuji S, Ugawa Y. Quantitative evaluation of cerebellar function in multiple system atrophy with transcranial magnetic stimulation. Cerebellum. (2021). doi: 10.1007/s12311-021-01293-0. [Epub ahead of print].
6. Fitzgibbon BM, Hoy KE, Knox LA, Guymer EA, Elliot D, et al. Evidence for the improvement of fatigue in fibromyalgia: a 4-week left dorsolateral prefrontal cortex repetitive transcranial magnetic stimulation randomized-controlled trial. Eur J Pain. (2018) 22:1255–67. doi: 10.1016/j.ejpain.2018.12.007
7. Wassermann EM, Lisanby SH. Therapeutic application of repetitive transcranial magnetic stimulation: a review. Clin Neurophysiol. (2001) 112:1367–77. doi: 10.1016/s1388-2457(01)00585-5
8. Song PH, Li S, Wang S, Wei H, Lin H, Wang YP. Repetitive transcranial magnetic stimulation of the cerebellum improves ataxia and cerebellar-fronto plasticity in multiple system atrophy: a randomized, double-blind, sham-controlled and TMS-EEG study. Aging (Albany NY). (2020) 12:20611–22. doi: 10.18632/aging.103946
9. França C, Andrade DC, Silva V, Galhardoni R, Barbosa ER, Teixeira MJ, et al. Effects of cerebellar transcranial magnetic stimulation on ataxias: a randomized trial. Parkinsonism Relat Disord. (2020) 80:1–6. doi: 10.1016/j.parkreldis.2020.09.001
10. Shibuya Y, Hanajima R, Shimizu T, Terao Y, Tsuji S, Ugawa Y. Quantitative evaluation of cerebellar function in multiple system atrophy with transcranial magnetic stimulation. Cerebellum. (2021). doi: 10.1007/s12311-021-01293-0. [Epub ahead of print].
11. Fitzgibbon BM, Hoy KE, Knox LA, Guymer EA, Elliot D, et al. Evidence for the improvement of fatigue in fibromyalgia: a 4-week left dorsolateral prefrontal cortex repetitive transcranial magnetic stimulation randomized-controlled trial. Eur J Pain. (2018) 22:1255–67. doi: 10.1016/j.ejpain.2018.12.007
12. Altsas EU, Askin A, Bejiorglu L, Tosun A. Is high-frequency repetitive transcranial magnetic stimulation of the left primary motor cortex superior to the stimulation of the left dorsolateral prefrontal cortex in fibromyalgia syndrome? Somatosens Mot Res. (2019) 36:56–62. doi: 10.1080/08990202.2019.1587400
13. Yang DG, Gu R, Kubo J, Kakuda W. Is the efficacy of repetitive transcranial magnetic stimulation influenced by baseline severity of fatigue symptom in patients with myalgic encephalomyelitis? Int J Neurosci. (2020) 150:64–70. doi: 10.1080/00207454.2019.1663189
14. Liu M, Fan S, Xu Y, Cui YX. Non-invasive brain stimulation for fatigue in multiple sclerosis patients: a systematic review and meta-analysis. Mult Scler Relat Disord. (2019) 36:10175. doi: 10.1016/j.msard.2019.08.017
15. Lefaucheur JP, André-Obadia N, Antal A, Ayache SS, Baeken C, Benninger DH, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). Clin Neurophysiol. (2014) 125:2150–206. doi: 10.1016/j.clinph.2014.05.021
16. Shin HW, Youn YC, Chung SJ, Sohn YH. Effect of high-frequency repetitive transcranial magnetic stimulation on major depressive disorder in patients with Parkinson’s disease. J Neurol. (2016) 263:1442–8. doi: 10.1007/s00415-016-8160-x

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Xuanwu Hospital Ethics Committee. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

PC, J-HM, and HS designed the study. JP carried out data collection, analyzed the data, and drafted the manuscript. PC and T-MM revised the manuscript. All authors have read and approved the final version for publication.

FUNDING

This work was supported by grants from the National Key R&D Program of China (Nos. 2018YFC1312001 and 2017YFC0840105), Beijing Municipal Administration of Hospitals’ Mission Plan (Code: SML20150803), Beijing Municipal Science and Technology Commission (No. Z171100000117013), and Inner Mongolia Natural Science Foundation (No. 2020MS08138).

ACKNOWLEDGMENTS

The authors thank patients for their participating in the project.
17. Randver R. Repetitive transcranial magnetic stimulation of the dorsolateral prefrontal cortex to alleviate depression and cognitive impairment associated with Parkinson’s disease: a review and clinical implications. J Neurol Sci. (2018) 393:88–99. doi: 10.1016/j.jns.2018.08.014

18. Dunlop K, Sheen J, Schulze L, Fettes P, Mansouri F, Fefker K, et al. Dorsomedial prefrontal cortex repetitive transcranial magnetic stimulation for treatment-refractory major depressive disorder: a three-arm, blinded, randomized controlled trial. Brain Stimul. (2020) 13:337–40. doi: 10.1016/j.brs.2019.10.020

19. Lefaucheur JP, Aleman A, Baeken C, Benninger DH, Brunelin J, Di LV, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): an update (2014–2018). Clin Neurophysiol. (2020) 131:474–528. doi: 10.1016/j.clinph.2019.11.002

20. Kluger BM, Krupp LB, Enoka RM. Fatigue and fatigability in neurologic illnesses: proposal for a unified taxonomy. Neurology. (2013) 80:409–16. doi: 10.1212/WNL.0b013e31827f07be

21. Siebner HR, Rothwell J. Transcranial magnetic stimulation: new insights into representational cortical plasticity. Exp Brain Res. (2003) 148:1–16. doi: 10.1007/s00221-002-1234-2

22. Bestmann S, Baudewig J, Siebner HR, Rothwell JC, Frahm J. BOLD MRI responses to repetitive TMS over human dorsal premotor cortex. Neuroimage. (2005) 28:22–9. doi: 10.1016/j.neuroimage.2005.05.027

23. Keck ME, Welt T, Müller MB, Erhardt A, Ohl F, Toschi N, et al. Repetitive transcranial magnetic stimulation increases the release of dopamine in the mesolimbic and mesostriatal system. Neuropharmacology. (2002) 43:101–9. doi: 10.1016/S0028-3908(02)00069-2

24. Strafella AP, Paus T, Barrett J, Dagher A. Repetitive transcranial magnetic stimulation of the human prefrontal cortex induces dopamine release in the caudate nucleus. J Neurosci. (2001) 21:RC157. doi: 10.1523/jneurosci.21-15-j0003.2001

25. Rothkegel H, Sommer M, Paulus W. Breaks during 5Hz rTMS are essential for facilitatory after effects. Clin Neurophysiol. (2010) 121:426–30. doi: 10.1016/j.clinph.2009.11.016

26. Daskalakis ZJ, Möller B, Christensen BK, Fitzgerald PB, Gunraj C, Chen R. The effects of repetitive transcranial magnetic stimulation on cortical inhibition in healthy human subjects. Exp Brain Res. (2006) 174:403–12. doi: 10.1007/s00221-006-0472-0

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Pan, Mi, Ma, Sun and Chan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.